Literature DB >> 35974431

Secretory carcinoma of the salivary gland: a multi-institutional clinicopathologic study of 90 cases with emphasis on grading and prognostic factors.

Bin Xu1, Kartik Viswanathan2, Kavita Umrau1, Thair A D Al-Ameri3, Snjezana Dogan1, Kelly Magliocca2, Ronald A Ghossein1, Nicole A Cipriani4, Nora Katabi1.   

Abstract

Secretory carcinoma (SC) is a rare form of salivary carcinoma that was first described in 2010 and is characterized by ETV6::NTRK3 fusion in most cases. In this large retrospective study, we aimed to identify adverse clinicopathologic factors and propose a prognostically relevant grading scheme for SC.
METHODS: A detailed clinicopathologic review was conducted on 90 SCs from the major and minor salivary glands.
RESULTS: The median age at presentation was 50 years (range: 7-93). Sixty-nine (77%) tumours originated from major salivary glands, whereas the remaining 21 involved minor salivary glands.Six cases (7%) had cervical nodal metastasis. Only lymphovascular invasion (LVI) was associated with a risk of nodal metastasis (P < 0.05). The 5-year disease-specific survival and disease-free survival (DFS) were 98% and 87%, respectively. On univariate survival analysis, adverse prognostic factors associated with decreased DFS included minor salivary gland origin, atypical mitosis, high mitotic index, high-grade transformation (HGT), necrosis, nuclear pleomorphism, infiltrative tumour border, fibrosis at the invasive front, LVI, positive margin, and advanced pT stage (P < 0.05). When adjusted for pT stage and margin status, mitotic index, LVI, nuclear pleomorphism, and HGT remained as independent prognostic factors.
CONCLUSION: We therefore propose a two-tiered grading system for SC. The low-grade SC is defined as those with <5 mitoses /10 high-power fields and no tumour necrosis, and high-grade SC as those with ≥5 mitoses /10 high-power fields and/or necrosis. This proposed grading system can be useful to risk stratify patients with SC for appropriate clinical management.
© 2022 John Wiley & Sons Ltd.

Entities:  

Keywords:  ETV6::NTRK3 fusion; Secretory carcinoma; grading; prognosis; salivary gland carcinoma

Mesh:

Substances:

Year:  2022        PMID: 35974431      PMCID: PMC9580072          DOI: 10.1111/his.14772

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   7.778


  31 in total

Review 1.  A systematic review of secretory carcinoma of the salivary gland: where are we?

Authors:  Lísia Daltro Borges Alves; Andreia Cristina de Melo; Thayana Alves Farinha; Luiz Henrique de Lima Araujo; Leandro de Souza Thiago; Fernando Luiz Dias; Héliton Spíndola Antunes; Ana Lucia Amaral Eisenberg; Luiz Claudio Santos Thuler; Daniel Cohen Goldemberg
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2020-05-31

2.  Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity.

Authors:  Ashton Connor; Bayardo Perez-Ordoñez; Mary Shago; Alena Skálová; Ilan Weinreb
Journal:  Am J Surg Pathol       Date:  2012-01       Impact factor: 6.394

3.  Clinicopathologic and molecular characterization of mammary analogue secretory carcinoma of salivary gland origin.

Authors:  F Baghai; F Yazdani; A Etebarian; A Garajei; A Skalova
Journal:  Pathol Res Pract       Date:  2017-07-23       Impact factor: 3.250

4.  Salivary Gland Secretory Carcinoma With High-Grade Transformation, CDKN2A/B Loss, Distant Metastasis, and Lack of Sustained Response to Crizotinib.

Authors:  Nicole A Cipriani; Elizabeth A Blair; Joshua Finkle; Jennifer L Kraninger; Christopher M Straus; Victoria M Villaflor; Daniel Thomas Ginat
Journal:  Int J Surg Pathol       Date:  2017-05-12       Impact factor: 1.271

5.  DOG1: a novel marker of salivary acinar and intercalated duct differentiation.

Authors:  Jacinthe Chênevert; Umamaheswar Duvvuri; Simion Chiosea; Sanja Dacic; Kathleen Cieply; Jean Kim; Daniel Shiwarski; Raja R Seethala
Journal:  Mod Pathol       Date:  2012-03-30       Impact factor: 7.842

6.  Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays.

Authors:  Sabah Kadri; Bradley C Long; Ibro Mujacic; Chao J Zhen; Michelle N Wurst; Shruti Sharma; Nadia McDonald; Nifang Niu; Sonia Benhamed; Jigyasa H Tuteja; Tanguy Y Seiwert; Kevin P White; Megan E McNerney; Carrie Fitzpatrick; Y Lynn Wang; Larissa V Furtado; Jeremy P Segal
Journal:  J Mol Diagn       Date:  2016-11-09       Impact factor: 5.568

7.  Mammary analog secretory carcinoma, low-grade salivary duct carcinoma, and mimickers: a comparative study.

Authors:  Todd M Stevens; Andra O Kovalovsky; Claudia Velosa; Qiuying Shi; Qian Dai; Randall P Owen; Walter C Bell; Shi Wei; Pamela A Althof; Jennifer N Sanmann; Larissa Sweeny; William R Carroll; Gene P Siegal; Martin J Bullock; Margaret Brandwein-Gensler
Journal:  Mod Pathol       Date:  2015-06-19       Impact factor: 7.842

8.  Head and Neck Acinic Cell Carcinoma: A New Grading System Proposal and Diagnostic Utility of NR4A3 Immunohistochemistry.

Authors:  Bin Xu; Maelle Saliba; Alan Ho; Kartik Viswanathan; Bayan Alzumaili; Snjezana Dogan; Ronald Ghossein; Nora Katabi
Journal:  Am J Surg Pathol       Date:  2022-01-17       Impact factor: 6.298

9.  Mammary analogue secretory carcinoma of salivary glands with high-grade transformation: report of 3 cases with the ETV6-NTRK3 gene fusion and analysis of TP53, β-catenin, EGFR, and CCND1 genes.

Authors:  Alena Skálová; Tomas Vanecek; Hanna Majewska; Jan Laco; Petr Grossmann; Roderick H W Simpson; Lukas Hauer; Pavel Andrle; Lubor Hosticka; Jindrich Branžovský; Michal Michal
Journal:  Am J Surg Pathol       Date:  2014-01       Impact factor: 6.394

10.  Mammary analogue secretory carcinoma of salivary glands: a new entity associated with ETV6 gene rearrangement.

Authors:  Hanna Majewska; Alena Skálová; Dominik Stodulski; Adéla Klimková; Petr Steiner; Czesław Stankiewicz; Wojciech Biernat
Journal:  Virchows Arch       Date:  2014-12-12       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.